Hogan Lovells names Lynn Mehler to lead the firm's Pharmaceutical & Biotechnology Regulatory practice

Hogan Lovells names Lynn Mehler to lead the firm's Pharmaceuticals & Biotechnology Regulatory practice

Press releases | 26 April 2022

Washington, D.C., 26 April 2022 – Global law firm Hogan Lovells announced today that Lynn Mehler has been named the Practice Area Leader for the firm’s Pharmaceuticals & Biotechnology Regulatory practice, succeeding Philip Katz. Mehler currently serves as co-head of the firm’s Life Sciences and Health Care industry sector and will continue in this role.

Janice Hogan, leader of the firm's Global Regulatory & Intellectual Property, Media, and Technology (IPMT) practice group, said: “With Lynn’s industry sector leadership and her extensive experience, she is well positioned to propel our premier Pharmaceuticals & Biotechnology Regulatory practice forward.” Hogan continued, “I am enormously grateful for the strong foundation Phil has built over the past nearly two decades, most recently helping clients navigate through the pandemic.”

Mehler joined Hogan Lovells as a partner in 2010, following 12 years with the FDA’s Office of the Chief Counsel. She advises pharmaceutical and biotechnology clients on a range of regulatory matters before the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA), including the approval processes for new drugs and biologics, safety issues such as the Risk Evaluation and Mitigation Strategies (REMS), and unique regulatory issues raised during the development and marketing of controlled substances. At the FDA, Mehler handled a broad range of pharmaceutical and controlled substances matters. She earned the FDA Commissioner's Award of Excellence, Commissioner's Award of Merit, and Outstanding Service Award for her contributions.

“The Pharmaceuticals & Biotechnology Regulatory practice at Hogan Lovells has long been recognized as one of the leading practices not only in Washington but globally, and I am honored to be entrusted to build on Phil’s outstanding leadership,” said Mehler. 

Katz, who has led the Pharmaceuticals & Biotechnology Regulatory practice since 2004, will continue with his practice, as well as continuing to play a leadership role guiding Diversity & Inclusion efforts for the firm’s Global Regulatory & IPMT practice. During his tenure, the practice has been recognized by Chambers as a Band 1 D.C. Pharmaceutical/Medical Products Regulatory group. Katz recently served as Chairman of the board of directors of the Food and Drug Law Institute (FDLI) and received the FDLI Distinguished Service and Leadership Award.